Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. The Company is focused on acquiring or funding programs and technologies that pharmaceutical companies use to discover and develop medicines. The Company’s Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Its Pelican Expression technology is a scalable platform for recombinant protein production, and is especially suited for complex, large-scale protein production. The Company’s products include Kyprolis, Teriparatide, Evomela, Rylaze, Nexterone, Pneumosil, Vaxneuvance, and Other. Kyprolis is formulated with Ligand’s Captisol technology. Teriparatide Injection is a drug indicated for uses including the treatment of osteoporosis in certain patients at high risk for fracture. Evomela is a Captisol-enabled melphalan IV formulation. Its other products include Pneumosil, Rylaze, Nexterone, Veklury, Zulresso, and Noxafil-IV.